CRHM
CRH Medical Corp
CRH Medical Corp historical holders
total: 1
Fairfax Financial Holdings CRH Medical Corp transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2021 Q2
Prem Watsa has been an institutional investor in CRH Medical Corp (CRHM) since 2021 Q1. According to 2026 Q1 report, Prem Watsa doesn't hold any shares. The fund/company first acquired CRHM in 2021 Q1, initially purchasing 270,000 shares. Since the initial investment, Fairfax Financial Holdings has made 1 more transaction in this position.
When did Prem Watsa exit their CRHM position?
Prem Watsa no longer holds CRH Medical Corp (CRHM). They sold off their entire position in 2021 Q2, closing out an investment that began in 2021 Q1.
When did Prem Watsa first invest in CRHM?
Prem Watsa first invested in CRH Medical Corp (CRHM) in 2021 Q1 at the reported quarter-end price of $3.95 per share, acquiring 270,000 shares in their initial purchase.
What is Prem Watsa's average cost basis for CRHM?
Based on historical transaction data, Prem Watsa's estimated cost basis for CRH Medical Corp (CRHM) is approximately $3.95 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $3.95
- Weighted AVG sell price:
- $3.95
CRHM transactions history by Fairfax Financial Holdings
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q2
|
0.00%
|
0
|
$3.95
|
|
-100% (-270,000)
|
-0.04%
|
|
2021 Q1
|
0.04%
|
270,000
|
$3.95
|
$1,067,000
|
new
|
+0.04%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.